Health Condition 1: C61- Malignant neoplasm of prostate
Conditions
Interventions
None listed
Sponsors
Apollo Proton Cancer Centre
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age more than 18 years 2. Patient with biopsy proven diagnosis of prostate cancer treated with proton beam at the Apollo Proton Cancer Centre. 3. Patient / guardian, who have the ability to understand and be willing to sign a written informed consent document
Exclusion criteria
Exclusion criteria: Patients or legal guardians who are not willing sign informed consent document
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Toxicity assessment Assessment of acute (during treatment and upto 6 weeks after completion of treatment), subacute (Post treatment 6 weeks to 6 months) and late (6 months to 5 years post treatment) toxicities using RTOG acute/late toxicity criteria. Timepoint: 1. Toxicity assessment Assessment of acute (during treatment and upto 6 weeks after completion of treatment), subacute (Post treatment 6 weeks to 6 months) and late (6 months to 5 years post treatment) toxicities using RTOG acute/late toxicity criteria. | — |
Secondary
| Measure | Time frame |
|---|---|
| Biochemical progression free survival (bPFS) for all patientsTimepoint: 0,1,2,3,4,5 years;Distant metastases free survival (DMFS) for all patientsTimepoint: 0,1,2,3,4,5 years;Overall survival (OS) for patientsTimepoint: 0,1,2,3,4,5 years;Quality of Life (QOL) assessment of all prostate cancer patients treated with PBT using EORTC QLQ PR-25 and EORTC QLQ-C30 for all patientsTimepoint: Pre-RT, post-RT, 3 months post-RT, 6 months post-RT, 1 year post-RT, 3 years post-RT, 5 years post-RT | — |
Countries
India
Contacts
Public ContactSrinivas Chilukuri
Apollo Proton Cancer Centre
Outcome results
None listed